Role of iron supplementation to erythropoiesis stimulating agents in the management of chemotherapy-induced anemia in cancer patients

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:To evaluate the benefits and harms associated with the use of iron as a supplement to ESA compared with ESA alone in the management of CIA. Our evaluation will focus on assessment of overall survival as the primary endpoint; and hematopoietic response, time to hematopoietic response, mean change in Hb level, RBC transfusions, treatment-related mortality, treatment-related harms, and QOL as secondary endpoints.